A blend of Sphaeranthus indicus flower head and Terminalia chebula fruit extracts reduces fatty liver and improves liver function in non-alcoholic, overweight adults
DOI:
https://doi.org/10.31989/ffhd.v12i7.958Abstract
Background: Excessive accumulation of fat in the liver is a common clinical presentation in non-alcoholic fatty liver disease (NAFLD). The increasing prevalence of NAFLD is a growing health problem worldwide. The major risk factors of NAFLD include obesity, hyperlipidemia, and insulin resistance.
Objective: The aim of the present randomized, double-blind, placebo-controlled clinical trial was to assess the efficacy and tolerability of an herbal composition CL16049F1 in reducing fatty liver conditions and improving liver function in non-alcoholic, overweight individuals. CL16049F1 is a patented© blend of Sphaeranthus indicus flower head and Terminalia chebula fruit extracts.
Materials and Methods: Ninety male and female subjects (age: 25-60 yrs., BMI: 23-29 kg/m2) with elevated Fatty Liver Index (FLI) between 31 and 59 were randomized into three groups (n=30). The participants received a daily dose of 300mg CL16049F1, 320 mg Silymarin, or a placebo over a period of 84 consecutive days. FLI was evaluated as the primary efficacy measure. The secondary efficacy measures included the liver enzymes, lipid profile, and oxidative stress markers in serum, A 36-Item Short-Form Health Survey (SF-36), and Gastrointestinal symptoms (GIS) score were also evaluated. The clinical biochemistry, hematology, urine, and vital signs were evaluated as safety measures. Adverse events were also monitored.
Results: Eighty-eight subjects completed the study. Post-trial, the FLI score of CL16049F1-supplemented subjects was reduced by 13.81% (p<0.05) and 16.08% (p<0.05), while the Silymarin supplemented group exhibited reductions of 7.50% (p<0.05) and 7.27% (p<0.05) as compared to baseline and placebo, respectively. CL16049F1 supplementation significantly improved the liver enzymes, lipid profile, and oxidative markers in serum. The changes in the secondary efficacy measures in these treatment groups are comparable. No major adverse events were observed.
Conclusion: CL16049F1 is a well-tolerated and effective herbal formulation to reduce fatty liver and improve liver function in non-alcoholic, overweight subjects.
Keywords: Non-alcoholic fatty liver disease, Fatty liver index, CL16049F1, hepatoprotective botanical formulation.
Downloads
Published
Issue
Section
License
Any manuscripts or substantial parts of it, submitted to the journal must not be under consideration by or previously published in any other journal or citable form. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights or the rights of a third party. In submitting one's article in any form, the author has assigned the FFC publishing rights and has agreed to an automatic transfer of the copyright to the publisher. This is so that the FFC may create print option journals, for example, at the FFC’s discretion. If the author wishes to distribute their works by means outside of the FFC, for example within their community, they will have to place a request.
Correspondence concerning articles published in Functional Foods in Health and Disease is encouraged. While derivative works (adaptations, extensions on the current work, etc.) are allowed, distribution of the modified material is not allowed without permission from the FFC.